Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $2.21 million. The enterprise value is -$6.10 million.
| Market Cap | 2.21M |
| Enterprise Value | -6.10M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 569,059 shares outstanding. The number of shares has increased by 1,177.57% in one year.
| Current Share Class | 569,059 |
| Shares Outstanding | 569,059 |
| Shares Change (YoY) | +1,177.57% |
| Shares Change (QoQ) | +2.29% |
| Owned by Insiders (%) | 18.24% |
| Owned by Institutions (%) | 2.35% |
| Float | 435,200 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.98 |
| Quick Ratio | 3.92 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -133.35% and return on invested capital (ROIC) is -83.44%.
| Return on Equity (ROE) | -133.35% |
| Return on Assets (ROA) | -69.44% |
| Return on Invested Capital (ROIC) | -83.44% |
| Return on Capital Employed (ROCE) | -165.18% |
| Weighted Average Cost of Capital (WACC) | 2.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.14% in the last 52 weeks. The beta is -0.10, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -87.14% |
| 50-Day Moving Average | 5.45 |
| 200-Day Moving Average | 7.63 |
| Relative Strength Index (RSI) | 41.77 |
| Average Volume (20 Days) | 25,738 |
Short Selling Information
The latest short interest is 6,605, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 6,605 |
| Short Previous Month | 1,581 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 0.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.71M |
| Pretax Income | -12.16M |
| Net Income | -17.84M |
| EBITDA | -12.68M |
| EBIT | -12.71M |
| Earnings Per Share (EPS) | -$39.98 |
Balance Sheet
The company has $9.12 million in cash and $805,399 in debt, with a net cash position of $8.32 million or $14.61 per share.
| Cash & Cash Equivalents | 9.12M |
| Total Debt | 805,399 |
| Net Cash | 8.32M |
| Net Cash Per Share | $14.61 |
| Equity (Book Value) | 7.23M |
| Book Value Per Share | 10.58 |
| Working Capital | 6.94M |
Cash Flow
In the last 12 months, operating cash flow was -$10.10 million and capital expenditures -$111,507, giving a free cash flow of -$10.21 million.
| Operating Cash Flow | -10.10M |
| Capital Expenditures | -111,507 |
| Depreciation & Amortization | 29,553 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.21M |
| FCF Per Share | -$17.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
REVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,177.57% |
| Shareholder Yield | -1,177.57% |
| Earnings Yield | -1,027.74% |
| FCF Yield | -461.31% |
Analyst Forecast
| Price Target | $124.25 |
| Price Target Difference | 3,094.09% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 20, 2026. It was a reverse split with a ratio of 1:7.
| Last Split Date | Oct 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |